<DOC>
	<DOCNO>NCT02093962</DOCNO>
	<brief_summary>The purpose study determine whether TH-302 combination pemetrexed safe effective treatment non-squamous non-small cell lung cancer .</brief_summary>
	<brief_title>Study TH-302 Placebo Combination With Pemetrexed Patients With Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description>TH-302 design target hypoxic region tumor generally locate distant tumor vessel . Pemetrexed poor tissue penetration target region tumor locate proximity tumor vessel . The presence hypoxia solid tumor associate malignant phenotype resistance chemotherapy . The hypoxia-activated prodrug , TH-302 , design selectively target hypoxic microenvironment . There evidence support presence hypoxia NSCLC lesion base hypoxia PET study . Combining pemetrexed TH-302 may enable target normoxic hypoxic region NSCLC lesion .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Phosphoramide Mustards</mesh_term>
	<criteria>Men woman ≥ 18 year age . Histologically cytologically confirm stage IIIB IV NSCLC nonsquamous histology Recurrent progressive disease one prior platinumbased nonpemetrexed chemotherapy treatment advance disease without maintenance Neoadjuvant/adjuvant cytotoxic chemotherapy initiate &lt; 12 month prior study randomization count one prior treatment Neoadjuvant/adjuvant cytotoxic chemotherapy initiate ≥ 12 month prior study randomization count one prior chemotherapy treatment Use target agent ( e.g. , monoclonal antibody kinase inhibitor ) count prior chemotherapy treatment Patients know EGFRactivating mutation ALK rearrangement receive treatment target kinase inhibitor ( e.g. , erlotinib , crizotinib ) longer consider candidate treatment Measurable disease accord RECIST 1.1 ECOG performance status 01 Resolution Grade ≤ 1 Adverse Events , clinically significant toxic effect prior therapy Adequate hematologic , hepatic , cardiac , renal function Female patient childbearing potential must negative serum urine pregnancy test , whichever consider standard institution Diagnosis small cell carcinoma lung , squamous cell carcinoma lung NSCLC NOS Prior therapy pemetrexed Inability unwillingness take folic acid , vitamin B12 supplementation corticosteroid Inability discontinue nonsteroidal antiinflammatory drug 5 day ( long halflife ) 2 day ( short halflife , CrCL &lt; 80 mL/min ) pemetrexed dose 2 day pemetrexed dose Leptomeningeal disease untreated symptomatic brain metastasis , unless follow criterion meet : brain metastasis stable previously treat either wholebrain radiotherapy gammaknife surgery steroid currently require 14 day since last steroid treatment Symptomatic pleural effusion ( &gt; CTCAE Grade 1 dyspnea ) amenable drainage Treatment systemic anticancer therapy within 4 week prior first dose study medication Treatment full field radiation therapy within 4 week limited field radiation therapy within 2 week prior first dose study medication Major surgery within 4 week minor surgery within 2 week prior first dose study medication Elective plan major surgery study treatment Radiation therapy great 25 % bone marrow Clinically significant active infection ( e.g . tuberculosis , viral hepatitis , HIV ) Any serious uncontrolled medical disorder psychological condition may interfere study conduct Concurrent active malignancy adequately treat basal cell squamous cell carcinoma skin preinvasive carcinoma cervix . Pregnant breast feeding Patients take medication prolong QT interval risk Torsades de Pointes ( Appendix F ) history long QT syndrome Patients take medication strong inducer inhibitor CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>TH-302</keyword>
	<keyword>TH-CR-415</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Evofosfamide</keyword>
</DOC>